← Pipeline
PreclinicalPreclinical programmePositive signal
Preclinical cell therapy
CRISPR-edited human OPCs
Engineered human oligodendrocyte progenitor cells
Practical availability: Preclinical — not available as a clinical intervention
- Compound / intervention
- Engineered human oligodendrocyte progenitor cells
- Mechanism
- Engineered oligodendrocyte progenitor-cell therapy
- Development stage
- Preclinical cell therapy
- Status
- Enhanced migration and remyelination in rodent chronic-lesion models
- Evidence level
- Preclinical only • no proven clinical benefit in MS
Next substantive checkpoint
Manufacturing, long-term safety and translational studies before human testing
Related substantive developments
No separate substantive update is currently linked.